{
  "id": 3401271,
  "title": "Ardelyx chief patient officer sells $41,419 in stock",
  "url": "https://urgent.news/2026/08/26/ardelyx-chief-patient-officer-sells-41-419-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T02:00:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ardelyx-chief-patient-officer-sells-41419-in-stock-93CH-4876179"
  },
  "original_language": "en",
  "account": "Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ:ARDX), divested 10,739 shares of the company's common stock on August 21, 2026. The shares, sold at prices ranging from $3.648 to $3.984 per share, were part of an automatic sell-to-cover to satisfy withholding taxes on restricted stock unit (RSU) awards. These transactions occurred after the RSU awards vested, leaving Ms. Williams with 367,456 shares of ARDELYX, INC. common stock directly held. The trading volume saw a rise in put options, reflecting increased investor concern about the company's future performance. Despite this, Ardelyx reported a 31% increase in its second-quarter revenue to a record $118 million, but revised its full-year guidance for IBSRELA and withdrew its revenue target for XPHOZAH. Analysts maintain a Strong Buy consensus, suggesting the stock is undervalued at current levels. The stock is trading near its 52-week low of $3.73, down 43% over the past six months. Investors are closely monitoring Ardelyx for future updates on its strategic direction and financial outlook.",
  "summary": null,
  "key_points": [
    "Chief Patient Officer Laura Williams sold 10,739 ARDX shares on Aug 21, 2026",
    "Shares sold at $3.648 to $3.984 per share to cover withholding taxes",
    "Ardelyx reported 31% Q2 revenue increase to $118M, revised full-year guidance"
  ],
  "editors_take": "The sale of Ardelyx shares by the Chief Patient Officer to cover tax obligations does not appear to have changed analyst consensus, which remains strongly bullish on the stock's prospects.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}